88/100BIntuitive Surgical stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Intuitive Surgical is 484.87, 9.3% above the current price of 443.58. Their targets range from 357.44 to 558.00.
Of the 23 firms that rated Intuitive Surgical in the past 12 months, 19 rate it buy or strong buy, 4 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 357.44 to 558.00, with an average of 484.87.
| Buy | 19 | |
| Hold | 4 | |
| Sell | 0 |
12-month price target
| Highest target | 558.00 |
| Average target | 484.87 |
| Lowest target | 357.44 |
| Current price | 443.58 |
Intuitive Surgical price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Intuitive Surgical price target and rating?
How analysts rate Intuitive Surgical, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
19 of 23 firms rate it buy now, against 10 of 14 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Intuitive Surgical analyst upgrades, downgrades and price targets
The latest rating change came on 12 August 2026, when Oppenheimer upgraded Intuitive Surgical from Perform to Outperform. The most recent new target came from Leerink Partners on 21 October 2026: 503.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 21 Oct 2026 | Leerink Partners Mike Kratky | Reiterated · Outperform | 454.00 → 503.00 | +10.8% | 423.35 |
| 21 Oct 2026 | RBC Capital | Reiterated · Outperform | 600.00 → 550.00 | -8.3% | 418.86 |
| 21 Oct 2026 | J.P. Morgan | — | 475.00 | — | 428.12 |
| 21 Oct 2026 | Oppenheimer Suraj Kalia | — | 500.00 | — | 438.00 |
| 21 Oct 2026 | Robert W. Baird | — | 500.00 → 550.00 | +10.0% | 438.00 |
| 21 Oct 2026 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 487.00 → 486.00 | -0.2% | 438.00 |
| 21 Oct 2026 | Barclays | Reiterated · Overweight | 485.00 → 500.00 | +3.1% | 438.00 |
| 21 Oct 2026 | Raymond James Jayson Bedford | — | 483.00 → 480.00 | -0.6% | 438.00 |
| 19 Oct 2026 | TD Cowen Matthew Blackman | — | 485.00 | — | 433.18 |
| 13 Oct 2026 | Mizuho Securities | — | 400.00 → 415.00 | +3.8% | 427.64 |
| 12 Oct 2026 | BTIG | Reiterated · Buy | 469.00 → 454.00 | -3.2% | 425.10 |
| 6 Oct 2026 | Barclays | — | 651.00 → 485.00 | -25.5% | 404.76 |
| 12 Aug 2026 | Oppenheimer | Upgraded · Perform → Outperform | — | — | — |
| 30 Jul 2026 | HSBC | Downgraded · Buy → Hold | 391.00 | — | 353.10 |
| 28 Jul 2026 | UBS Priya Sachdeva | — | 570.00 → 500.00 | -12.3% | 356.83 |
| 27 Jul 2026 | Piper Sandler | — | 470.00 → 357.44 | -23.9% | 358.35 |
| 17 Jul 2026 | Raymond James Jayson Bedford | Reiterated · Outperform | 603.00 → 483.00 | -19.9% | 356.77 |
| 17 Jul 2026 | Mizuho Securities | Reiterated · Neutral | 500.00 → 400.00 | -20.0% | 402.33 |
| 17 Jul 2026 | BTIG | Reiterated · Buy | 512.00 → 469.00 | -8.4% | 402.33 |
| 17 Jul 2026 | Piper Sandler Adam Maeder | Reiterated · Overweight | 580.00 → 470.00 | -19.0% | 402.33 |
| 17 Jul 2026 | Stifel Nicolaus Rick Wise | Reiterated · Buy | 670.00 → 550.00 | -17.9% | 402.33 |
| 17 Jul 2026 | Robert W. Baird | — | 655.00 → 500.00 | -23.7% | 402.33 |
| 17 Jul 2026 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 487.00 | — | 402.33 |
| 17 Jul 2026 | Leerink Partners Mike Kratky | Reiterated · Outperform | 454.00 | — | 402.33 |
| 16 Jul 2026 | Truist Financial | Reiterated · Buy | 580.00 → 510.00 | -12.1% | 399.34 |
| 15 Jul 2026 | Mizuho Securities | Reiterated · Neutral | 525.00 → 500.00 | -4.8% | 379.50 |
| 14 Jul 2026 | Stifel Nicolaus Rick Wise | — | 670.00 | — | 407.12 |
| 13 Jul 2026 | RBC Capital | Reiterated · Outperform | 650.00 → 600.00 | -7.7% | 408.89 |
| 13 Jul 2026 | BTIG | — | 616.00 → 512.00 | -16.9% | 406.78 |
| 8 Jul 2026 | BMO Capital | — | 518.00 | — | 415.10 |
| 6 Jul 2026 | Evercore ISI | Reiterated · In Line | 550.00 → 430.00 | -21.8% | 422.04 |
| 2 Jun 2026 | Piper Sandler Adam Maeder | — | 620.00 → 580.00 | -6.5% | 397.61 |
| 27 May 2026 | Goldman Sachs | — | 714.00 → 558.00 | -21.8% | 436.64 |
| 23 Apr 2026 | Barclays | Reiterated · Overweight | 712.00 → 651.00 | -8.6% | 483.62 |
| 15 Apr 2026 | Truist Financial | Reiterated · Buy | 650.00 → 580.00 | -10.8% | 472.02 |
| 13 Apr 2026 | Mizuho Securities | Reiterated · Neutral | 575.00 → 525.00 | -8.7% | 450.47 |
| 11 Mar 2026 | Citigroup | Upgraded · Neutral → Buy | — | — | — |
| 24 Feb 2026 | UBS | Reiterated · Neutral | 600.00 → 570.00 | -5.0% | 491.00 |
| 27 Jan 2026 | Freedom Capital Markets | Upgraded · Hold → Buy | — | — | — |
| 26 Jan 2026 | Barclays | Reiterated · Overweight | 686.00 → 712.00 | +3.8% | 523.99 |
| 26 Jan 2026 | Freedom Broker | Upgraded · Hold → Buy | — | — | — |
| 23 Jan 2026 | Evercore ISI Vijay Kumar | Reiterated · In Line | 580.00 → 550.00 | -5.2% | 523.60 |
| 23 Jan 2026 | Piper Sandler | Reiterated · Overweight | 610.00 → 620.00 | +1.6% | 525.81 |
| 23 Jan 2026 | Bernstein | Reiterated · Outperform | 740.00 → 750.00 | +1.4% | 525.81 |
| 9 Jan 2026 | Bernstein | Reiterated · Outperform | 685.00 → 740.00 | +8.0% | 585.08 |
| 9 Jan 2026 | Goldman Sachs | — | 714.00 | — | 585.08 |
| 7 Jan 2026 | BTIG | Reiterated · Buy | 589.00 → 616.00 | +4.6% | 592.85 |
| 7 Jan 2026 | Barclays | Reiterated · Overweight | 686.00 | — | 592.85 |
| 5 Jan 2026 | Evercore ISI | — | 580.00 | — | 565.96 |
| 18 Dec 2025 | Truist Financial | Reiterated · Buy | 620.00 → 650.00 | +4.8% | 565.57 |
Intuitive Surgical EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Intuitive Surgical's EPS to grow 21.3% a year until 2028. Over the last 5 years it grew 21.8% a year, and over the last 3 years 29.2%.
Analysts expect Intuitive Surgical's revenue to grow 14.2% a year until 2028, slower than over the last 5 years (18.2% a year) and the last 3 years (17.4%).
Revenue
EPS
Does Intuitive Surgical beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 12.9% off the result, either way, and their revenue estimate 3.5%, over the last 12 quarters.
- EPS beats
- 82 / 104
- Revenue beats
- 84 / 104
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +12.9%
- Since
- July 2000
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 20 Oct 2026 | 2.65 | 3.00 | +13.2% | 2.91B | 3.05B | +4.9% |
| Q2 FY2026 | 16 Jul 2026 | 2.51 | 2.80 | +11.6% | 2.83B | 2.89B | +2.4% |
| Q1 FY2026 | 21 Apr 2026 | 2.51 | 2.80 | +11.6% | 2.62B | 2.77B | +5.8% |
| Q4 FY2025 | 22 Jan 2026 | 2.27 | 2.53 | +11.5% | 2.76B | 2.87B | +3.7% |
| Q3 FY2025 | 21 Oct 2025 | 1.99 | 2.40 | +20.6% | 2.41B | 2.51B | +4.1% |
| Q2 FY2025 | 22 Jul 2025 | 1.93 | 2.19 | +13.5% | 2.35B | 2.44B | +3.8% |
| Q1 FY2025 | 22 Apr 2025 | 1.74 | 1.81 | +4.0% | 2.19B | 2.25B | +3.1% |
| Q4 FY2024 | 23 Jan 2025 | 1.76 | 2.21 | +25.6% | 2.25B | 2.41B | +7.3% |
| Q3 FY2024 | 17 Oct 2024 | 1.63 | 1.84 | +12.9% | 2.01B | 2.04B | +1.6% |
| Q2 FY2024 | 18 Jul 2024 | 1.54 | 1.78 | +15.6% | 1.97B | 2.01B | +1.9% |
| Q1 FY2024 | 18 Apr 2024 | 1.41 | 1.50 | +6.4% | 1.87B | 1.89B | +1.1% |
| Q4 FY2023 | 23 Jan 2024 | 1.48 | 1.60 | +8.1% | 1.89B | 1.93B | +2.1% |
Intuitive Surgical stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Intuitive Surgical's earnings grow at the 16.3% a year analysts expect to FY2028, then 15.0% a year, it would earn about 18.56 a share in FY2030. At the P/E of similar companies (Medical - Instruments & Supplies, 22.1 to 58.8) that is 410.45 to 1,090.39 a share, or 754.46 at their average P/E of 40.7. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 11.26 | 249.01 | 457.71 | 661.50 |
| FY2027 | 12.49 | 276.21 | 507.71 | 733.77 |
| FY2028 | 14.03 | 310.36 | 570.48 | 824.49 |
| FY2029 (extrapolated) | 16.14 | 356.91 | 656.05 | 948.17 |
| FY2030 (extrapolated) | 18.56 | 410.45 | 754.46 | 1,090.39 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Its own P/E has been above 60, or from losses, too often in the last five years, so bear, base and bull apply the lowest, average and highest P/E of similar companies (Medical - Instruments & Supplies: 22.1, 40.7, 58.8), those up to 60.
Is Intuitive Surgical stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Intuitive Surgical's P/E of 53.0 is near the bottom of its 5-year range (37.5 to 96.4, median 69.6). Analysts expect slower growth than in recent years, so the low P/E may be deserved. Buyers pay less for each point of growth than usual: a PEG of 2.5 on expected growth against 3.2 on its median P/E and past five years' growth. At its usual P/E (70.7 × EPS of 8.37), Intuitive Surgical's fair value is 591.36; the price, 443.58, is 25.0% below it. Its forward P/E, on the consensus for FY2026, is 39.4.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (37.5 and 96.4). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 53.00
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 69.62
- Five-year P/E range
- 37.5 – 96.4
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 39.40
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.26
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +9.3%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.